The current P/E ratio of CTLT cannot be calculated, as the latest EPS of -$7.19 is negative. The last PE ratio of Catalent, recorded in March 2023, was 547.58.
The PE ratio of Catalent has averaged 92.08 over the last ten years. Analyzing the last ten years, CTLT's PE ratio reached its highest point in the Sep 2014 quarter at 1,251.5, when the price was $25.03 and the EPS was $0.02. The lowest point was recorded in the Sep 2015 quarter, when it reached 12.21 with a price of $24.3 and an EPS of $1.99.
Maximum annual increase: 64.08% in 2018
Maximum annual decrease: -45.69% in 2021
| Year | PE ratio | Change |
|---|---|---|
| 2023 | N/A | N/A |
| 2022 | 39.16 | 14.1% |
| 2021 | 34.32 | -45.69% |
| 2020 | 63.19 | 7.25% |
| 2019 | 58.92 | -9.98% |
| 2018 | 65.45 | 64.08% |
| 2017 | 39.89 | 54.43% |
| 2016 | 25.83 | 55.88% |
| 2015 | 16.57 | N/A |
| 2014 | N/A | N/A |
| Stock name | PE ratio | Market cap |
|---|---|---|
| EGRX Eagle Pharmaceuticals Inc | 4.78 | $57.14M |
| JAZZ Jazz Pharmaceuticals plc | 20.9 | $6.89B |
| SUPN Supernus Pharmaceuticals Inc | 1,513.5 | $1.66B |
| MACK Merrimack Pharmaceuticals Inc | N/A | $218.18M |
| CTLT Catalent Inc | N/A | $10.18B |
The current price to earnings ratio of CTLT cannot be determined, as its EPS of -$7.19 is negative.
The 3-year average PE ratio for CTLT stock is 99.26.
The 5-year average PE ratio for CTLT stock is 77.87.
Over the last ten years, the quarterly PE ratio reached its highest level at 1,251.5 in the Sep 2014 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.